Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0910 Reg QTs
BioCentury & Getty Images


Sept. 10 Quick Takes: approvals for Zai, GSK and Phase III readouts for Satsuma, Amryt and Takeda; plus Houston Methodist, MassBio and JPM

Sep 11, 2020 | 1:30 AM GMT

China approves Zejula as first-line maintenance for ovarian cancer
China's National Medical Products Administration (NMPA) approved an sNDA from Zai Lab Ltd. (NASDAQ:ZLAB) for Zejula niraparib as a first-line maintenance therapy in ovarian cancer patients in

Read the full 684 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers